Adalvo is pleased to announce the successful DCP submission for Macitentan 10mg film-coated tablets, developed in collaboration with one of our strategic partners.
This product is based on the reference brand Opsumit 10mg film-coated tablets, which is indicated in the treatment of Pulmonary Arterial Hypertension, a rare and highly debilitating orphan disease.
The brand sold approximately $1.4bn globally in 2022, with a Global 3Y CAGR of +3%, according to IQVIA.
Adalvo proudly stands among the first companies to file on day one in Europe. This achievement reflects our dedication to advancing healthcare solutions efficiently and showcases our commitment to bringing innovative therapies to market promptly.
Partner up now!
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
bruno.alves@adalvo.com - Brazil
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!